CRISPR Therapeutics AG (NASDAQ:CRSP) and Myovant Sciences Ltd. (NYSE:MYOV) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Myovant Sciences Ltd.||11||0.00||29.56M||-3.80||0.00|
Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for CRISPR Therapeutics AG and Myovant Sciences Ltd.
Table 2 demonstrates the return on assets, return on equity and net margins of CRISPR Therapeutics AG and Myovant Sciences Ltd.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,388,545.67%||-2.6%||-2%|
|Myovant Sciences Ltd.||272,191,528.55%||-768.5%||-140.4%|
CRISPR Therapeutics AG’s Current Ratio is 8.3 while its Quick Ratio is 8.3. On the competitive side is, Myovant Sciences Ltd. which has a 2.8 Current Ratio and a 2.8 Quick Ratio. CRISPR Therapeutics AG is better positioned to pay off short and long-term obligations compared to Myovant Sciences Ltd.
The next table highlights the shown recommendations and ratings for CRISPR Therapeutics AG and Myovant Sciences Ltd.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Myovant Sciences Ltd.||0||0||2||3.00|
CRISPR Therapeutics AG has an average price target of $72, and a 10.16% upside potential. Competitively Myovant Sciences Ltd. has an average price target of $23, with potential upside of 52.82%. Based on the analysts view we can conclude, Myovant Sciences Ltd. is looking more favorable than CRISPR Therapeutics AG.
Institutional and Insider Ownership
The shares of both CRISPR Therapeutics AG and Myovant Sciences Ltd. are owned by institutional investors at 46.8% and 41.4% respectively. Insiders owned 0.4% of CRISPR Therapeutics AG shares. Competitively, Myovant Sciences Ltd. has 49.9% of it’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Myovant Sciences Ltd.||-6.74%||195.03%||139.34%||80.54%||-10.7%||1.22%|
For the past year CRISPR Therapeutics AG was more bullish than Myovant Sciences Ltd.
CRISPR Therapeutics AG beats on 7 of the 10 factors Myovant Sciences Ltd.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.